Live-attenuated Salmonella species are effective carriers of microbial antigens and DNA vaccines. In a mouse model, the immunoglobulin M (IgM) and total antibody levels directed toward the lipopolysaccharide of Salmonella enterica serovar Typhi were significantly enhanced at day 21 after oral immunization with liveattenuated serovar Typhi (strain Ty21a) when ampicillin was concomitantly administered (P < 0.05 and P < 0.005, respectively). The heat-killed Ty21a-stimulated lymphocyte proliferation indices for the ampicillin group at day 21 were significantly higher than those for the normal saline (NS) group (P < 0.005, P < 0.001, and P < 0.01) for all three doses of antigen (10 4 , 10 5 , and 10 6 heat-killed Ty21a per well, respectively). The 50% lethal doses for mice from the ampicillin and NS groups immunized with Ty21a with pBR322 after wild-type serovar Typhi challenge on day 24 were 3.4 ؋ 10 7 and 5.0 ؋ 10 6 CFU, respectively. The fecal bacterial counts for the ampicillin group at days 1, 3, and 5 were significantly lower than those for the NS group (P < 0.01, P < 0.01, and P < 0.05, respectively), and there was a trend toward recovery of Ty21a in a larger number of mice from the ampicillin group than from the NS group. Furthermore, the IgG2a levels directed toward tetanus toxoid were significantly enhanced at days 7 and 21 after oral immunization with Ty21a that carried the fragment c of tetanus toxoid when ampicillin was concomitantly administered (P < 0.05 and P < 0.005, respectively), and the IgM and total hepatitis B surface antibody levels were significantly enhanced at days 7 (P < 0.005 and P < 0.05, respectively) and 21 (P < 0.01 and P < 0.05, respectively) after oral immunization with Ty21a that carried the DNA vaccine that encodes hepatitis B surface antigen when ampicillin was concomitantly administered. The present observation may improve the efficacy of the protein antigens and DNA vaccines carried in live-attenuated bacteria, and further experiments should be carried out to determine the best antibiotics and dosage regimen to be used, as well as the best carrier system for individual protein antigens and DNA vaccines.
Mucosal vaccination provides specific advantages for ease of administration, vaccine formulation, and potential to support mass vaccination (7) . It has been shown that live-attenuated Salmonella species are effective carriers of microbial antigens and DNA vaccines (3, 5, 13) . However, since the efficacy of oral live-attenuated Salmonella enterica serovar Typhi vaccine (Ty21a) in humans is only 70% (14, 15) , it can be inferred that use of strain Ty21a as a vaccine carrier for human beings is far from ideal. Moreover, the immunogenicities of mucosal vaccines in people who reside in developing countries are even worse (8, 12) . This would further hinder the potential use of Ty21a as a vaccine carrier for global immunization. Therefore, new ways to improve the immunogenicity of Ty21a as well as the protein antigens and DNA vaccines carried in it are mandatory.
Antibiotics have been known to affect immune responses (16, 17, 18) . Recently, we have shown that antibiotics, especially ampicillin, enhance the antibody response against the lipopolysaccharide (LPS) of serovar Typhi after intraperitoneal Ty21a immunization in a mouse model (16) . In these experiments, the effects of ampicillin on the immunogenicity of oral Ty21a and the protein antigen and DNA vaccine carried in it were studied. We examined the effects of ampicillin on the serum antibody response against LPS of serovar Typhi, the heatkilled Ty21a-stimulated lymphocyte proliferation index (LPI), and the survival of mice upon wild-type S. typhi challenge after oral Ty21a immunization. We also studied the effect of ampicillin on the serum antibody response against tetanus toxoid and hepatitis B surface antigen (HBsAg) in mice administered fragment c of tetanus toxoid and the DNA that encodes HBsAg, each of which was carried in Ty21a, respectively. The possible mechanism of such effects is also discussed.
MATERIALS AND METHODS

Animals.
Female BALB/c mice (weight, 18 to 22 g) were used in all experiments. They were housed in cages under standard conditions with regulated day length, temperature, and humidity and were given pelleted food and tap water ad libitum.
Experimental schedule, antibiotic administration, and immunization. The mice were divided randomly into two groups; one group received ampicillin (20 mg/kg of body weight) intraperitoneally, and the other group received 0.25 ml of sterile normal saline (NS). The doses were administered from day Ϫ1 to day 20. To determine the effect of ampicillin on the levels of antibodies against LPS of S. enterica serovar Typhi in serum, the heat-killed Ty21a-stimulated LPI, the survival of mice upon wild-type serovar Typhi challenge, and the fecal aerobic bacterial and Ty21a counts after Ty21a administration, 39 mice from the ampicillin group and 39 mice from the NS group were immunized orally with Ty21a (Berna, Berne, Switzerland) that had been transformed with pBR322 (Amersham Pharmacia Biotech, Piscataway, N.J.) (to make the organism ampicillin resistant) by using a gastric tube (2.7 ϫ 10 9 CFU in 0.3 ml). Fifteen mice from each group were used for measurement of serum antibody levels, LPI, fecal bacterial count, and Ty21a isolation; and the remaining 24 mice in each group were used for wild-type serovar Typhi challenge. For determination of the effect of ampicillin on the antibody response after immunization with the expressed protein antigen carried in Ty21a, 15 mice from the ampicillin group and 15 mice from the NS group were immunized orally with Ty21a transformed with pTETnir15 (a gift from A. J. Makoff) (2.7 ϫ 10 9 CFU in 0.3 ml), which contained fragment c of tetanus toxoid under the control of a prokaryotic promoter (2) . Furthermore, for determination of the effect of ampicillin on the antibody response after immunization with DNA carried in Ty21a, 15 mice from the ampicillin group and 15 mice from the NS group were immunized orally with Ty21a transformed with pRc/CMV-HBs(S) (a gift from Robert Whalen) (2.7 ϫ 10 9 CFU in 0.3 ml), which contained HBsAg under the control of a cytomegalovirus (CMV) promoter (4) .
Measurement of levels of antibodies against LPS of serovar Typhi, tetanus toxoid, and HBsAg in serum. Fifteen mice from each group were bled on days Ϫ1, 7, and 21 (9). Blood was taken right before administration of antibiotics. The blood was centrifuged at 2,700 ϫ g for 20 min, and the serum was stored at Ϫ70°C before antibody level measurement.
Nunc-Immuno plates (Nalge Nunc International, Roskilde, Denmark) were used in all enzyme-linked immunosorbent assay (ELISA) experiments for measurement of antibody levels against tetanus toxoid and LPS of S. typhi. Each well was coated with 100 l of diluted antigen (50 l of tetanus toxoid in 50 l of 0.05 M carbonate-bicarbonate buffer [pH 9.6] or 4 g LPS of S. typhi in 0.05 M carbonate-bicarbonate buffer [pH 9.6]), and the plates were incubated at 4°C overnight. After the plate was washed with phosphate-buffered saline (PBS)-0.05% Tween 20 (washing buffer) twice 200 l of PBS-5% bovine serum albumin (BSA) (blocking buffer) was added to each well and the plate was incubated at 37°C for 2 h. After the plate was washed with washing buffer three times, mouse sera (diluted 1:25 with PBS-2% BSA) were added to the ELISA plates. For measurement of levels of antibody against HBsAg, mouse sera (diluted with PBS-2% BSA) were added to ELISA plates precoated with HBsAg (Biokit, Barcelona, Spain). The plates were incubated at 37°C for 1 h. After the plates were washed with washing buffer three times, 100 l of peroxidase-conjugated goat anti-mouse antibody (anti-mouse total antibody from DAKO, Glostrup, Denmark; anti-mouse immunoglobulin M [IgM], IgG1, and IgG2a from Serotect, Kidlington, United Kingdom) that was diluted, according to the manufacturer's instructions, with PBS-2% BSA was added to the each well and the plate was incubated at 37°C for 30 min (tetanus toxoid and HBsAg) or 1 h (Ty21a). Assays for IgM and total antibody levels were conducted to assess the primary and secondary immune responses, while IgG1 and IgG2a levels were used to determine whether the humoral response was inclined toward the Th2 or the Th1 pattern, respectively. After the plate was washed with washing buffer three times, 100 l of ortho-phenylenediamine (OPD) substrate (prepared by diluting 2 mg of OPD [Calbiochem, La Jolla, Calif.] in 2.5 ml of 50 mM citric acid [pH 5] with 2.5 l of 30% H 2 O 2 ) was added to each well and the plate was incubated at room temperature for 30 min. A total of 100 l of 1 M H 2 SO 4 was added and the absorbance of each well was measured at 492 nm, with OPD buffer used as a blank. Each sample was tested in duplicate, and the mean absorbance for each serum sample was calculated. All ELISAs were optimized so that there was a linear relationship between the optical density and the amount of antibody present in the serum at the serum dilution for the corresponding type of antibody measured. The serum antibody level for a particular mouse on a particular day was defined as the absorbance obtained from the serum on that day minus that for the corresponding mouse on day Ϫ1. Control experiments were performed by adding ampicillin to serum samples to exclude the possibility of interference of ampicillin with the ELISA.
Measurement of LPI. On day 21, single-cell suspensions of spleen cells from 15 mice in the ampicillin group and 15 mice in the NS group that had been immunized with Ty21a with pBR322 were depleted of erythrocytes by adding freshly prepared Gey's solution. The cells were resuspended in RPMI 1640 medium (Gibco BRL, Rockville, Md.) supplemented with 15% fetal calf serum and were inoculated into microwell plates at 5 ϫ 10 5 cells per well in triplicate. The cells were stimulated with phytohemagglutinin at 5 g per well (positive control), heat-killed Ty21a at concentrations of 10 4 , 10 5 , and 10 6 bacteria per well, or RPMI 1640 medium (negative control). Cells were cultured at 37°C in 5% CO 2 for 3 days, and 3 H-labeled thymidine (Amersham Pharmacia, Little Chalfont, United Kingdom) was added at 1 Ci per well for the last 18 h. The cells were harvested onto glass-fiber filter mats with a model CH1 cell harvester (Insel, Hampshire, United Kingdom), and radioactivity was measured in a liquid scintillation counter (Beckman, Fullerton, Calif.). The LPI for a particular sample is defined as the ratio of the difference in radioactivity between the positive control and the sample and that between the positive and negative controls.
Measurement of fecal bacterial counts. On the day before immunization and on days 1, 3 and 5 after immunization, the feces of 15 mice (0.01 g of feces per mouse) from the ampicillin and NS groups immunized with Ty21a with pBR322 were collected and resuspended in 1 ml of PBS. Each sample was further diluted 1:200,000 with PBS, and 100 l from each diluted sample was plated onto cystine-lactose-electrolyte-deficient agar in duplicate. The plates were incubated at 37°C for 48 h. The number of colonies on each plate was counted, and the fecal counts of the mice were expressed as the number of CFU per gram of stool.
Isolation of fecal Ty21a from immunized mice. On days 1, 2, and 3, the feces of 15 mice (0.01 g of feces per mouse) from the ampicillin and NS groups that had been immunized with Ty21a with pBR322 were collected and resuspended in 2 ml of Selenite-F broth. After incubation at 37°C for 24 h, 10 l from each resuspended sample was plated onto Luria-Bertani agar with ampicillin (100 mg/ ml). The plates were incubated at 37°C for 48 h. Suspected colonies were isolated and confirmed to be Ty21a by standard biochemical tests and serotyping (10) .
Determination of LD 50 by wild-type challenge with serovar Typhi. On day 24, when the serum ampicillin levels of the mice had fallen to negligible levels, groups of six mice each from the ampicillin group and the NS group that had been immunized with Ty21a with pBR322 were challenged with graded doses (8.9 ϫ 10 7 , 3.4 ϫ 10 7 , 1.3 ϫ 10 7 , and 5.0 ϫ 10 6 CFU) of wild-type S. typhi. The lengths of survival of the mice were recorded. The 50% lethal doses (LD 50 s) for the ampicillin and NS groups were defined as the administered dose of wild-type S. typhi that caused the death of 50% of the mice in each groups.
Statistics. The serum antibody levels, LPI, and fecal bacterial counts between the mice in the ampicillin and NS groups that received Ty21a with pBR322 were compared by Student's t test, as were the serum antibody levels between those that received Ty21a with fragment c of tetanus toxoid or DNA that encoded HBsAg. A P value of Ͻ0.05 is regarded as statistically significant.
RESULTS
Antibodies against LPS of serovar Typhi in serum.
The levels of total antibody and antibody subtypes against LPS of S. enterica serovar Typhi in serum at days 7 and 21 after oral administration of Ty21a with pBR322 to mice treated with ampicillin or NS is summarized in Table 1 . The IgM levels of the ampicillin group at days 7 and 21 and the total antibody levels for the ampicillin group at day 21 were significantly higher than the corresponding antibody levels for the NS group (P Ͻ 0.05, P Ͻ 0.05, and P Ͻ 0.005, respectively).
LPI. The heat-killed Ty21a-stimulated LPI at day 21 after oral administration of Ty21a with pBR322 to mice treated with ampicillin or NS is summarized in Table 2 . The LPIs for the ampicillin group at day 21 when 10 4 , 10 5 , and 10 6 heat-killed Ty21a per well were used as antigens were significantly higher than those for the NS group (P Ͻ 0.005, P Ͻ 0.001, and P Ͻ 0.01, respectively).
LD 50 after wild-type serovar Typhi challenge. The survival of mice in the ampicillin and NS groups immunized with Ty21a with pBR322 after intraperitoneal challenge with wild-type serovar Typhi on day 24 is shown in Table 3 . The LD 50 s for mice from the ampicillin and NS groups were 3.4 ϫ 10 7 and 5.0 ϫ 10 6 CFU, respectively. Fecal bacterial counts. The fecal bacterial counts at day Ϫ1 and days 1, 3, and 5 after oral administration of Ty21a with pBR322 to mice treated with ampicillin or NS is summarized in Table 4 . The fecal bacterial counts for the ampicillin group at days 1, 3, and 5 were significantly lower than those for the NS group (P Ͻ 0.01, P Ͻ 0.01, and P Ͻ 0.05, respectively).
Fecal Ty21a isolation. The number of mice from which Ty21a was isolated in the feces on days 1, 2, and 3 after oral administration of Ty21a with pBR322 to mice treated with ampicillin or NS is summarized in Table 5 . There was a trend toward the recovery of Ty21a in a larger number of mice from the ampicillin group than from the NS group.
Levels of antibodies against tetanus toxoid in serum. The levels of total antibody and antibody subtypes against tetanus toxoid in serum at days 7 and 21 after oral administration of Ty21a with pTETnir15 to mice treated with ampicillin or NS is summarized in Table 6 . The IgG2a levels for the ampicillin group at days 7 and 21 were significantly higher than the corresponding antibody levels for the NS group (P Ͻ 0.05 and P Ͻ 0.005, respectively).
Levels of antibodies against HBsAg in serum. The levels of total antibody and antibody subtypes against HBsAg in serum at days 7 and 21 after oral administration of Ty21a with pRc/ CMV-HBs(S) to mice treated with ampicillin or NS is summarized in Table 7 . The IgM and total antibody levels for the ampicillin group at days 7 (P Ͻ 0.005 and P Ͻ 0.05, respectively) and 21 (P Ͻ 0.01 and P Ͻ 0.05, respectively) were significantly higher than the corresponding antibody levels for the NS group.
DISCUSSION
Ampicillin improved the B-cell response, the antigen-specific T-cell response, and the protective immune response after oral Ty21a immunization. Previously, we showed that antibiotics, especially ampicillin, enhanced the humoral immune response of mice immunized intraperitoneally with Ty21a (16) . In the present study, we showed that ampicillin enhanced not only the humoral immune response of mice after oral Ty21a immunization but also the heat-killed Ty21a-stimulated LPI for all three doses of heat-killed Ty21a used. Furthermore, the LD 50 for the group of mice that received ampicillin was sevenfold higher than that for the group that received NS.
The immunogenicity of the DNA vaccine or protein antigen carried in Ty21a was also enhanced by administration of ampicillin. In our experiments the HBsAg DNA vaccine and the fragment c of tetanus toxoid were chosen as the DNA vaccine and the protein antigen carried in Ty21a, respectively, because we have previously shown that ampicillin does not affect the antibody response of mice induced by parenteral administration of recombinant HBsAg or tetanus toxoid (16) . In the present study, we showed that ampicillin increased the serum IgM response induced by pRc/CMV-HBs(S) carried in Ty21a. This is in line with the evidence that the major immune response induced by a single intraperitoneal dose of recombinant HBsAg vaccine is IgM. The IgG response occurred only after administration of a booster dose (16) . On the other hand, ampicillin enhanced the IgG2a response induced by tetanus toxoid fragment c carried in Ty21a. This is probably because the tetanus toxoid fragment carried in Ty21a is presented by the antigen-presenting cells in a manner different from that when it is given through the subcutaneous route. When given subcutaneously, tetanus toxoid was presented mainly through the major histocompatibility complex class II pathway, inducing mainly antibody responses of the Th2 type (IgM and IgG1). However, when the tetanus toxoid fragment is carried in Ty21a, it is presented through intracellular major histocompatibility complex class I pathways, shifting the antibody response toward Th1. Therefore, it is not surprising that the major serum antibody subtype level that is upregulated is IgG2a. Furthermore, this is in line with the finding of a previous study, which showed that a strong class I-restricted cytotoxic T-cell response against murine lymphocytic choriomeningitis virus was induced by the chimeric protein formed between the nu- clear protein of the virus and an S. enterica serovar Typhimurium effector protein carried in live-attenuated serovar Typhimurium (13) . Ampicillin enhanced the immune response of oral Ty21a probably by giving it a survival advantage against the normal bacterial flora of the intestine. We showed that ampicillin significantly suppressed the normal flora of the intestine, resulting in a relatively higher rate of recovery of Ty21a from the feces on days 1, 2, and 3. This is in line with the M-cell sampling theory about antigen presentation in the mucosa of the gastrointestinal tract. It has been shown that S. enterica serovar Typhi cells adhere selectively to the M cells of mucosaassociated lymphoid tissue, which form the gateway of the mucosal immune system (1, 6) . This induces engulfment of the bacteria by "macrocytosis." The engulfed Salmonella will be presented to the T and B lymphocytes that form large intraepithelial pockets around the basolateral membranes of the M cells (11) . The normal flora of the murine large intestine, which contains 10 8 bacteria per gram of feces, competes with Ty21a by occupying the mucosal adhesion sites, competing with Ty21a for nutrients, and secreting bacteriocins and bacteriocin-like substances. When ampicillin is administered, the normal flora is transiently suppressed 100-fold, giving Ty21a a survival advantage and a greater chance of presenting itself and the protein antigen or DNA vaccine carried in it to the M cells.
These observations have important applications for both prophylactic and therapeutic vaccinations. The problem of disease transmission through the use of reusable needles for immunization is of great concern in developing countries. Mucosal vaccination provides specific advantages in terms of ease of administration, vaccine formulation, and the potential to support mass vaccination (7) . Besides the induction of an immune response to the microorganism itself, live-attenuated bacteria that carry protein antigens are used to induce an immune response against the protein antigen carried in them (5, 13) , and the type of immune response can be further tuned with the help of adjuvants. However, the protective efficacy of oral Ty21a in humans is only about 70%, and this is even worse in developing countries, where people suffer from environmental enteropathy, with their gastrointestinal tracts, especially their upper gastrointestinal tracts, being colonized with many more bacteria than those of people in developed countries (8, 12) . Therefore, this concept of antibiotic enhancement of the immune response might have a place in selective prophylactic vaccination programs, such as vaccination of nonresponders to routine immunization. Furthermore, DNA vaccination is considered a possible way for therapeutic vaccination, including the treatment of cancer. Therefore, the present observations may improve the therapeutic effect of DNA vaccines carried in live-attenuated bacteria, and further experiments should be carried out to determine the best antibiotics and dosage regimens to be used, as well as the best carrier system for individual protein antigens and DNA vaccines. However, with concerns about the increasing rate of antibiotic resistance worldwide, the incorporation of an antibiotic as part of a routine vaccination regimen is probably not warranted. 
